Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
High Dose Inhaled Nitric Oxide in Critically Ill Pneumonia Patients
NCT06950294Phase 1Recruiting
- Sponsor
- Massachusetts General Hospital
- Start
- Feb 2026
- Primary completion
- Dec 2026
- Modality
- DNA Intercalators/Alkylators, Inhalation Devices
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of nitric oxide in pneumonia (2 arms), sponsored by Massachusetts General Hospital. Primary endpoint: Peaks of methomoglobin. Started Feb 2026; status: recruiting.
02
Drugs
nitric oxide
03
Conditions
pneumonia
Beyond the preview
Go deeper on NCT06950294.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06950294.